Here, we identified GRPR89A as a previously undescribed therapeutic target in NSCLC cells and found that cisplatin treatment in GPR89A knockout cells increased cell death following cell cycle arrest in the S phase. This evidence concerns the gene GPHRA and non-small cell lung carcinoma.